Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NB1011 in Fluoropyrimidine-Resistant Metastatic or Relapsed Colorectal Cancer
NCT00031616Phase 2Unknown
- Sponsor
- New Biotic
- Start
- Dec 2001
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thymectacin in colorectal cancer (CRC), sponsored by New Biotic. Primary endpoints: Maximum Tolerated Dose, Safety and Toxic Effects and 2 more. Status: unknown.
02
Drugs
thymectacin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00031616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031616.